Free Trial

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

-0.20 (-3.33%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.59 million shs
Average Volume
2.88 million shs
Market Capitalization
$898.36 million
P/E Ratio
Dividend Yield
Price Target

Ocular Therapeutix MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
161.5% Upside
$15.17 Price Target
Short Interest
13.61% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth
From ($0.91) to ($0.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

300th out of 915 stocks

Pharmaceutical Preparations Industry

137th out of 423 stocks

OCUL stock logo

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock Price History

OCUL Stock News Headlines

Ocular Therapeutix: Q1 Earnings Snapshot
Ocular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDR
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$59.84 million
Book Value
$2.63 per share


Free Float
Market Cap
$898.36 million
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 56)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Jeffrey S. Heier M.D. (Age 63)
    Chief Scientific Officer
    Comp: $84.88k
  • Dr. Rabia Gurses Ozden M.D. (Age 55)
    Chief Medical Officer
    Comp: $621.39k
  • Dr. Pravin U. Dugel M.D. (Age 60)
    Executive Chairman
  • Dr. Karen-Leigh Edwards M.B.A.
    Ph.D., Chief Operations Officer
  • Dr. Peter K. Jarrett Ph.D. (Age 67)
    Chief Technology Officer
  • Mr. Philip C. Strassburger Esq. (Age 64)
    General Counsel
    Comp: $282.61k
  • Mr. William H. Ransone II
    Vice President of Global Sales & Marketing
  • Ms. Tracy Smith
    Vice President of Human Resources

OCUL Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price target for 2024?

6 equities research analysts have issued 1-year price targets for Ocular Therapeutix's stock. Their OCUL share price targets range from $7.00 to $22.00. On average, they anticipate the company's stock price to reach $15.17 in the next year. This suggests a possible upside of 161.5% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2024?

Ocular Therapeutix's stock was trading at $4.46 at the beginning of 2024. Since then, OCUL stock has increased by 30.0% and is now trading at $5.80.
View the best growth stocks for 2024 here

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our OCUL earnings forecast

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.06. The biopharmaceutical company had revenue of $14.77 million for the quarter, compared to analysts' expectations of $15.43 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 76.64% and a negative net margin of 192.61%.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.68%), Avoro Capital Advisors LLC (4.62%), Deltec Asset Management LLC (1.59%), Price T Rowe Associates Inc. MD (0.43%), Essex Investment Management Co. LLC (0.24%) and Banco Santander S.A. (0.13%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden and Summer Road Llc.
View institutional ownership trends

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUL) was last updated on 5/24/2024 by Staff

From Our Partners